Towa Pharmaceutical Co., Ltd.

DB:6QC Stock Report

Market Cap: €929.7m

Towa Pharmaceutical Future Growth

Future criteria checks 1/6

Towa Pharmaceutical's earnings are forecast to decline at 3.1% per annum while its annual revenue is expected to grow at 5.9% per year. EPS is expected to decline by 3.1% per annum. Return on equity is forecast to be 8.4% in 3 years.

Key information

-3.1%

Earnings growth rate

-3.1%

EPS growth rate

Pharmaceuticals earnings growth17.9%
Revenue growth rate5.9%
Future return on equity8.4%
Analyst coverage

Low

Last updated29 Oct 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:6QC - Analysts future estimates and past financials data (JPY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2027298,38416,05610,09529,4955
3/31/2026279,11414,3057,10028,2675
3/31/2025261,54212,648-8,92029,1805
6/30/2024235,95216,918-25,68810,647N/A
3/31/2024227,93416,173-30,6948,212N/A
12/31/2023236,77911,735N/AN/AN/A
9/30/2023225,7556,462-41,269-270N/A
6/30/2023218,0355,556N/AN/AN/A
3/31/2023208,8592,201-27,9102,544N/A
12/31/2022180,4072,898N/AN/AN/A
9/30/2022173,8619,364-7,7236,118N/A
6/30/2022168,06011,998N/AN/AN/A
3/31/2022165,61515,9148,63622,129N/A
12/31/2021165,26219,511N/AN/AN/A
9/30/2021162,51416,9498,47220,785N/A
6/30/2021159,92715,934N/AN/AN/A
3/31/2021154,90013,9582,37012,008N/A
12/31/2020141,23012,981N/AN/AN/A
9/30/2020129,67413,6886,51513,171N/A
6/30/2020119,87814,074N/AN/AN/A
3/31/2020110,38414,50314,49419,164N/A
12/31/2019111,21813,989N/AN/AN/A
9/30/2019111,31514,36416,02622,234N/A
6/30/2019108,01613,673N/AN/AN/A
3/31/2019105,10413,4757,64819,002N/A
12/31/2018101,3099,577N/AN/AN/A
9/30/201897,8718,3697,70319,755N/A
6/30/201896,4118,056N/AN/AN/A
3/31/201893,4306,495N/A19,230N/A
12/31/201791,6608,145N/AN/AN/A
9/30/201789,1269,794N/A11,457N/A
6/30/201787,2858,680N/AN/AN/A
3/31/201784,9495,576N/A10,195N/A
12/31/201684,5826,180N/AN/AN/A
9/30/201683,4743,755N/A11,304N/A
6/30/201682,8624,345N/AN/AN/A
3/31/201682,1157,684N/A3,732N/A
12/31/201579,6498,521N/AN/AN/A
9/30/201577,16411,064N/A3,621N/A
6/30/201574,41412,076N/AN/AN/A
3/31/201571,47011,118N/A8,037N/A
12/31/201469,1819,758N/AN/AN/A
9/30/201466,2608,041N/A8,836N/A
6/30/201463,2326,075N/AN/AN/A
3/31/201461,3515,992N/A8,144N/A
12/31/201358,7626,342N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6QC's earnings are forecast to decline over the next 3 years (-3.1% per year).

Earnings vs Market: 6QC's earnings are forecast to decline over the next 3 years (-3.1% per year).

High Growth Earnings: 6QC's earnings are forecast to decline over the next 3 years.

Revenue vs Market: 6QC's revenue (5.9% per year) is forecast to grow faster than the German market (5.5% per year).

High Growth Revenue: 6QC's revenue (5.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 6QC's Return on Equity is forecast to be low in 3 years time (8.4%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y